Your Article Summary
See Latest Articles(Click the title below to leave the MDLinx Network and go to the Journal's Website)
Dey L.P. to Market EMSAM Skin Patch for Treatment of Major Depressive Disorder
Mylan, 06/01/09
Dey L.P., a subsidiary of Mylan Inc. , announced that it has begun to market and distribute EMSAM in the U.S. EMSAM, a selegiline transdermal system, is a monoamine oxidase inhibitor, which was approved by the U.S. Food and Drug Administration in 2006 for the treatment of major depressive disorder.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Prodesses ProParaflu+(TM) Assay Cleared for US Marketing by FDA
Gen-Probe, 12/03/09
Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
Shire, 12/03/09
Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/25/09